Answers are grounded in this paper and cite their sources.
Clear cell renal cell carcinoma (ccRCC) is characterized by profound metabolic reprogramming, with glutamine addiction emerging as a central hallmark that extends beyond supporting tumor proliferation. This review synthesizes current knowledge on how glutamine metabolic reprogramming remodels the immunosuppressive tumor microenvironment and modulates immunotherapy response in renal cell carcinoma. The molecular basis of glutamine addiction is discussed, focusing on the von Hippel‑Lindau/hypoxia‑inducible factor axis, MYC activation and epigenetic regulation. The mechanisms by which glutamine metabolism orchestrates immune evasion are examined, including tumor immune cell competition, impaired effector T‑cell function, expansion of immunosuppressive populations such as regulatory T cells and M2 polarized macrophages, and upregulation of immune checkpoints. Therapeutic strategies targeting glutamine metabolism, from transporter and glutaminase inhibition to dietary restriction, are summarized along with mixed clinical trial outcomes that underscore the need for patient selection. Candidate predictive biomarkers across genetic, metabolic, immune and imaging domains are also reviewed. This review aims to provide an integrated framework for understanding glutamine‑driven immune modulation and to guide future therapeutic development in ccRCC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: